A randomised clinical trial investigating the effect of pemetrexed versus docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy

1 Treatments

- **Studied treatment**: pemetrexed 500 mg/m² intravenously (i.v.) day 1 with vitamin B(12), folic acid, and dexamethasone

- **Control treatment**: docetaxel 75 mg/m² i.v. day 1 with dexamethasone every 21 days

2 Patients

- **Patients**: patients with advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy

3 Methods

- **Blinding**

- **Design**

- **Centers**

- **Geographical area**

- **Sample size**: 571 (283 / 288)

- **ArretTrt1**

- **ArretTrt0**

- **PeriodeInclusion**

- **Hypothese**: PEM
# Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>OS</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>PFS</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>ORR</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>

## References


## Comments